Pre-operative Aceclofenac on the Anesthetic Efficacy of IANB in Symptomatic Irreversible Pulpitis

Effect of Pre-operative Aceclofenac on the Anesthetic Efficacy of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial

The aim of this randomized, double-blinded, controlled study is to evaluate the effect of pre-operative oral aceclofenac on the success of the inferior alveolar nerve block with 2% Mepivacaine containing 100,000 Epinephrine for patients with symptomatic irreversible pulpitis.

• The aim of this randomized, double-blinded, controlled study is to evaluate the effect of pre-operative oral aceclofenac on the success of the inferior alveolar nerve block with 2% Mepivacaine containing 100,000 Epinephrine for patients with symptomatic irreversible pulpitis.
• Patients will be clinically and radiographically examined and their eligibility will be assessed and preoperative pain will be measured using Heft-Parker VAS. Eligible patients will be treated in one visit.
• Patients will be randomly assigned to one of 2 groups: experimental group (taking a 100 mg of Aceclofenac) and the control group (taking a placebo tablet). Each tablet will be taken one hour before starting treatment. After 15 minutes of the initial inferior alveolar nerve block (IANB), the teeth will be examined using a cold pulp sensitivity test; in case of no or mild pain, the treatment will be initiated otherwise, additional IANB will be administered.
• During root canal treatment, no to mild pain response will be considered success. In case of failure, supplemental anesthesia will be administrated.

Inclusion Criteria:

• Patients in good health (American Society of Anesthesiologists Class I or Class II).
• Patients having symptomatic irreversible pulpitis in one of their mandibular molars
• Age is 18 years or older.
• Patients who can understand Heft- Parker Visual Analogue Scales.
• Patients able to sign informed consent.

Exclusion Criteria:

• Patients allergic to aceclofenac or Mepivacaine.
• Pregnant or nursing women.
• Patients having active pain in more than one molar in the same quadrant.
• Administration of analgesics within 12 h before the administration of the study drug.